Company Overview
NovoCure Limited functions as an oncology company dedicated to the development, manufacture, and commercialization of tumor treating fields (TTFields) devices designed for the treatment of solid tumor cancers. The company operates within the Healthcare sector, specifically the Medical Devices industry, where it provides specialized therapeutic technology to markets including the United States, Germany, France, Japan, Greater China, and international regions. Its operational scale is defined by a market capitalization of $1.36B, an annual revenue of $655.35M, and an employee base of 1605. These valuation and revenue figures indicate that NovoCure holds a significant position within the medical device landscape, reflecting substantial market confidence despite the capital-intensive nature of developing and deploying oncology-specific hardware.
Financial Health
The company reported revenue of $655.35M for the trailing twelve months, yet recorded a net income of $-136,227,008 and an EBITDA of $-135,159,008, revealing a cost structure where operating expenses significantly exceed gross profits. This gap between the $655.35M in revenue and the negative earnings highlights the substantial burn rate associated with commercializing complex medical technologies like TTFields devices. Free cash flow stands at $-37,975,376, indicating that the company is currently using cash reserves to fund operations and growth initiatives rather than generating excess liquidity. Margins show a gross margin of 74.8%, suggesting high pricing power or low cost of goods sold, but this is offset by an operating margin of -21.3% and a profit margin of -20.8%, which reflect heavy investment in sales, general, and administrative costs. On the balance sheet, the company holds $447.67M in cash against $248.35M in debt, resulting in a debt-to-equity ratio of 72.94, which suggests a leveraged position given the negative earnings but maintains liquidity coverage. The current ratio of 2.90 indicates strong short-term liquidity, demonstrating that the company possesses nearly three times the current assets required to meet its short-term obligations. Return on equity is reported at -38.9% and return on assets at -9.1%, metrics that reveal management is currently deploying capital to generate negative returns, typical for growth-stage biotech and medical device firms.
Valuation Assessment
Valuation metrics present a complex picture, with a P/E Ratio (TTM) listed as N/A due to the net loss, while the forward P/E is recorded at -10.26, implying that the market prices in future earnings expectations that have not yet materialized. The price-to-book ratio stands at 3.94, indicating that the market values the company at nearly four times its book value, which may reflect intangible assets or future growth potential rather than current asset backing. Alternative valuation measures include a price-to-sales ratio of 2.07 and an EV/EBITDA of -8.47, suggesting that investors are willing to pay a premium for sales volume despite current losses. The stock has traded between a 52-week low of $9.82 and a 52-week high of $20.06, and without a specific current price provided in the facts, the trading range defines the recent volatility envelope for the security. The beta value of 0.74 suggests that the stock's price volatility is lower than the broader market, moving less aggressively than the overall market index during periods of fluctuation.
Growth & Income
Revenue growth for the trailing twelve months was 8.1%, while earnings growth is N/A due to the company's recent net loss status, indicating that profitability is lagging behind top-line expansion. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute income to shareholders, meaning all available earnings are retained to fund research, development, and commercialization efforts. This reinvestment strategy aligns with the company's growth profile, prioritizing the expansion of its TTFields device footprint and technological advancements over immediate income distribution. Overall, NovoCure Limited presents a growth-oriented profile characterized by revenue expansion and significant capital allocation toward future profitability rather than current shareholder yield.